Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.
Clinical trial NCT05323890 · UNKNOWN
Trial details
- NCT number
- NCT05323890
- Sponsor
- Shandong Cancer Hospital and Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-20
- Primary completion
- 2023-10-20
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.